Literature DB >> 9536336

Osteoporosis in rheumatoid arthritis.

Y Suzuki1, Y Mizushima.   

Abstract

Periarticular osteopenia of appendicular bones occurs early in the course of RA. Loss of the balance between bone resorption and formation contributes to the development of periarticular osteopenia and might be mediated through increased production of cytokines and prostaglandins by the synovium and bone marrow. Generalized osteopenia is also common and leads to an increased risk of fracture. Although the pathogenesis of this osteopenia is considered to be multifactorial, disease activity, immobility, corticosteroids and menopausal status are the important determinants.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9536336     DOI: 10.1007/bf03194376

Source DB:  PubMed          Journal:  Osteoporos Int        ISSN: 0937-941X            Impact factor:   4.507


  39 in total

1.  Fractures in children treated with methotrexate for leukemia.

Authors:  S Stanisavljevic; A L Babcock
Journal:  Clin Orthop Relat Res       Date:  1977-06       Impact factor: 4.176

2.  Excessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritis.

Authors:  T Hirano; T Matsuda; M Turner; N Miyasaka; G Buchan; B Tang; K Sato; M Shimizu; R Maini; M Feldmann
Journal:  Eur J Immunol       Date:  1988-11       Impact factor: 5.532

3.  Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy.

Authors:  Y Suzuki; Y Ichikawa; E Saito; M Homma
Journal:  Metabolism       Date:  1983-02       Impact factor: 8.694

4.  Production of collagenase and prostaglandins by isolated adherent rheumatoid synovial cells.

Authors:  J M Dayer; S M Krane; R G Russell; D R Robinson
Journal:  Proc Natl Acad Sci U S A       Date:  1976-03       Impact factor: 11.205

5.  Methotrexate osteopathy in rheumatic disease.

Authors:  S J Preston; T Diamond; A Scott; M R Laurent
Journal:  Ann Rheum Dis       Date:  1993-08       Impact factor: 19.103

6.  Spinal trabecular bone mineral content in patients with non-steroid treated rheumatoid arthritis.

Authors:  J E Compston; E O Crawley; C Evans; M M O'Sullivan
Journal:  Ann Rheum Dis       Date:  1988-08       Impact factor: 19.103

7.  The effect of low-dose methotrexate on bone metabolism and histomorphometry in rats.

Authors:  K P May; S G West; M T McDermott; W E Huffer
Journal:  Arthritis Rheum       Date:  1994-02

8.  Iliac crest trabecular bone mass and structure in patients with non-steroid treated rheumatoid arthritis.

Authors:  R W Mellish; M M O'Sullivan; N J Garrahan; J E Compston
Journal:  Ann Rheum Dis       Date:  1987-11       Impact factor: 19.103

9.  Interleukin-1 beta stimulates bone resorption and inhibits bone formation in vivo.

Authors:  L Nguyen; F E Dewhirst; P V Hauschka; P Stashenko
Journal:  Lymphokine Cytokine Res       Date:  1991-04

10.  Periarticular osteopenia in adjuvant induced arthritis: role of interleukin-1 in decreased osteogenic and increased resorptive potential of bone marrow cells.

Authors:  Y Suzuki; M Tanihara; Y Ichikawa; A Osanai; M Nakagawa; M Ide; Y Mizushima
Journal:  Ann Rheum Dis       Date:  1995-06       Impact factor: 19.103

View more
  12 in total

1.  Relation of interleukin-6 in rheumatoid arthritis patients to systemic bone loss and structural bone damage.

Authors:  Mona Helmy Abdel Meguid; Yousry Hasan Hamad; Rania Shafek Swilam; Mohamed Samy Barakat
Journal:  Rheumatol Int       Date:  2012-04-25       Impact factor: 2.631

2.  Osteoporosis Update 1997. Symposium proceedings. Osaka, Japan, 13-16 November 1997.

Authors: 
Journal:  Osteoporos Int       Date:  1997       Impact factor: 4.507

3.  Assessment of phalangeal bone loss in patients with rheumatoid arthritis by quantitative ultrasound.

Authors:  P Röben; R Barkmann; S Ullrich; A Gause; M Heller; C C Glüer
Journal:  Ann Rheum Dis       Date:  2001-07       Impact factor: 19.103

4.  The treatment of osteoporosis in patients with rheumatoid arthritis receiving glucocorticoids: a comparison of alendronate and intranasal salmon calcitonin.

Authors:  Funda Tascioglu; Omer Colak; Onur Armagan; Ozkan Alatas; Cengiz Oner
Journal:  Rheumatol Int       Date:  2005-02-02       Impact factor: 2.631

5.  [Clinical trial for differentiation between corticoid-induced osteoporosis and periarticular demineralization via digital radiogrammetry in patients suffering from rheumatoid arthritis].

Authors:  J Böttcher; A Pfeil; G Lehmann; B Heinrich; A Malich; A Hansch; A Petrovitch; H-J Mentzel; G Hein; W A Kaiser
Journal:  Z Rheumatol       Date:  2004-12       Impact factor: 1.372

6.  The effect of low-dose methotrexate on bone mineral density in patients with early rheumatoid arthritis.

Authors:  Funda Tascioglu; Cengiz Oner; Onur Armagan
Journal:  Rheumatol Int       Date:  2003-03-21       Impact factor: 2.631

7.  Bone mineral density in patients with early rheumatoid arthritis treated with corticosteroids.

Authors:  George S Habib; Shehadeh Haj
Journal:  Clin Rheumatol       Date:  2004-09-14       Impact factor: 2.980

8.  Increased frequency of temporal acoustic window failure in rheumatoid arthritis: a manifestation of altered bone metabolism?

Authors:  Zsófia Kardos; Csaba Oláh; Mariann Sepsi; Attila Sas; László Kostyál; Tünde Bóta; Harjit Pal Bhattoa; Katalin Hodosi; György Kerekes; László Tamási; Dániel Bereczki; Zoltán Szekanecz
Journal:  Clin Rheumatol       Date:  2018-01-30       Impact factor: 2.980

9.  Does low-dose and short-term glucocorticoids treatment increase the risk of osteoporosis in rheumatoid arthritis female patients?

Authors:  Izabela Korczowska; Anna Olewicz-Gawlik; Jakub Trefler; Paweł Hrycaj; Jan Krzysztof Łacki
Journal:  Clin Rheumatol       Date:  2007-10-02       Impact factor: 2.980

10.  Infliximab prevents systemic bone loss and suppresses tendon inflammation in a collagen-induced arthritis rat model.

Authors:  Frideriki Poutoglidou; Chryssa Pourzitaki; Maria Eleni Manthou; Efthimios Samoladas; Athanasios Saitis; Foteini Malliou; Dimitrios Kouvelas
Journal:  Inflammopharmacology       Date:  2021-05-12       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.